Expression data from Jurkat cells treated with SB225002 for 6h and 9h.

In our efforts to evaluate the function of the IL-8 receptor CXCR2 in Acute Lymphoblastic Leukemia (ALL) cells, we made use of SB225002 (N-(2-hydroxy-4-nitrophenyl)-N’-(2-bromophenyl)urea), a drug initially described as a CXCR2 antagonist. Although the CXCR2 receptor was found to be non-functional in ALL, B- and T-ALL cell lines were sensitive to SB225002. We used microarray analysis to identify a transcriptional profile of genes that mediate SB225002's effects in acute lymphoblastic leukemia cells. Jurkat cells were treated for 6h or 9h with SB225002 [12.5 uM] or 0.1% DMSO (vehicle control).

本研究旨在评估白细胞介素8受体CXCR2在急性淋巴细胞白血病（Acute Lymphoblastic Leukemia，ALL）细胞中的功能，选用了SB225002（N-(2-羟基-4-硝基苯基)-N'-(2-溴苯基)脲）——一种最初被报道为CXCR2拮抗剂的化合物。尽管研究发现CXCR2受体在急性淋巴细胞白血病细胞中无功能，但B细胞型和T细胞型急性淋巴细胞白血病细胞系对SB225002均表现出敏感性。我们通过微阵列（microarray）分析，鉴定出了介导SB225002在急性淋巴细胞白血病细胞中产生生物学效应的基因转录谱。实验中，将Jurkat细胞以12.5 μM浓度的SB225002或0.1%二甲基亚砜（DMSO，溶剂对照）分别处理6小时或9小时。